GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million:
GE HealthCare agreed to buy SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal, expected to close in early 2027, includes SOFIE's 15 U.S. manufacturing sites and rights to FAPI-74, an experimental PET imaging agent. SOFIE will continue serving existing customers post-acquisition. Trilantic North America, SOFIE's private equity backer, sold the company to GE HealthCare, which aims to expand its pharmaceutical diagnostics segment.
How this was made
The 30-second read
Why it matters
The acquisition provides GE with a distributed manufacturing footprint for short‑lived isotopes and U.S. rights to a late‑stage imaging agent, potentially boosting its competitive position.
Market read
The deal is a material M&A event for a large‑cap healthcare company, likely influencing sector dynamics and investor sentiment.
What to watch
Regulatory approval risk for the acquisition and integration challenges of a distributed cyclotron network may delay value realization.
Background
GE HealthCare is expanding its pharmaceutical diagnostics segment by acquiring a specialized contract manufacturer of PET radiopharmaceuticals.
Ticker impact
GE HealthCare announced a $945 million cash acquisition of SOFIE Biosciences, a contract manufacturer of PET radiopharmaceuticals.
likely modest upside as the market prices in the strategic premium and growth potential of the PET network.
Large‑cap M&A announcements typically lift the acquirer’s stock, especially when the target adds unique capabilities and the purchase price is modest relative to cash reserves.
Market effects
Strengthens the healthcare diagnostics and radiopharmaceutical manufacturing subsector, potentially prompting peers to explore similar acquisitions.
U.S. PET imaging supply chain gains a domestic player, which may improve regional supply reliability.
Adds to the global trend of consolidation in medical imaging, influencing investor sentiment toward med‑tech stocks worldwide.
Counterpoint
The cash outlay could strain GE HealthCare's balance sheet and dilute earnings per share, prompting a short‑term pullback.
Key entities
- companyGE HealthCare
U.S. listed med‑tech firm acquiring SOFIE Biosciences.
- companySOFIE Biosciences
Private contract manufacturer of PET radiopharmaceuticals.
